Nyrada Inc Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Key Metrics
PE ratio
-
PB ratio
54.12
Dividend yield
-
Beta
0.92
Market cap
$225.05M
Enterprise value
$191.11M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://www.nyrada.com |
| Mailing address | Sydney Place Level 22/23, Salesforce Tower 180 George Street Sydney NSW 2000 Australia |
| Phone / Fax | 61 2 9498 3390 / 61 2 9416 0810 |
Dividends
More: Nyrada Inc Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Nyrada Inc paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.NYR dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Nyrada Inc.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. James Bonnar | CEO, MD & Director | ||
| Mr. Cameron Peter Jones C.A. | Chief Financial Officer | ||
| Mr. Benjamin Evison Ph.D. | Chief Scientific Officer | ||
| Mr. Dimitri Burshtein | Investor Relations Manager | ||
| Mr. Mark Waring B.Sc., P.M.P. | Senior Vice President of US Operations | ||
| Mr. David James Franks BEc, C.A., F Fin, J.P. | Company Secretary | 55 |
Profitability and management effectiveness
Profit margin
-202.18%
Operating margin
-152.71%
Return on assets
-55.85%
Return on equity
-112.32%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Nyrada Inc is 225.05M and its enterprise value is 191.11M. The enterprise value to revenue ratio of NYR is 79.74. The enterprise value to EBITDA ratio of NYR is -38.19.
The NYR's stocks Beta value is 0.92 making it 8% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Nyrada Inc (NYR)
Nyrada Inc (ASX:NYR) Frequently Asked Questions
1. What is Nyrada Inc's Stock Symbol?
Nyrada Inc trades on ASX under the ticker symbol "NYR".
2. What is Nyrada Inc's stock price today?
One share of NYR stock can currently be purchased for approximately $0.92.
3. How can I contact Nyrada Inc?
Nyrada Inc's mailing address is Sydney Place Level 22/23, Salesforce Tower 180 George Street Sydney NSW 2000 Australia. The company can be reached via phone at 61 2 9498 3390.
4. What is Nyrada Inc's official website?
The official website of Nyrada Inc is https://www.nyrada.com.